30 augustus 2021

World-first trial tests cannabis-based drug on aggressive brain tumours

A major UK trial of cannabis-based drug Sativex in treating the most aggressive form of brain tumour is to launch at 15 NHS hospitals, following promising results from a phase I study in 27 patients.

The new phase II trial, led by the University of Leeds, will assess whether adding Sativex – an oral spray containing cannabinoids THC and CBD – to chemotherapy, could extend life for thousands diagnosed with a recurrent glioblastoma. Currently, it has an average survival of less than 10 months.

The drug, already used in treating multiple sclerosis, was found to be tolerable in combination with chemotherapy, with the potential to extend survival, in a phase I trial in glioblastomas earlier this year.

Read the whole article

Share this on Facebook
Thanks to our friends @
CNNBS

RELATED NEWS

first cannabis graduate
21 juli 2021

First medical Cannabis degree USA

The University of Maryland in May graduated its first class enrolled in its master’s program for medical marijuana studies. The program, the first of its kind in the nation, is...

more